The objectives of this study are to assess the impacts of meals composed of lean steak and potatoes (with a small portion of broccoli) in comparison to other common entrée/starch food combinations on metabolic and appetite responses.

开始日期2024-08-07

申办/合作机构

San Diego State University

100 项与帕米醇相关的临床结果

登录后查看更多信息

100 项与帕米醇相关的转化医学

登录后查看更多信息

100 项与帕米醇相关的专利（医药）

登录后查看更多信息

2,998

项与帕米醇相关的文献（医药）

2025-12-01·CURRENT ALLERGY AND ASTHMA REPORTS

Treatment of COVID-19 Associated Olfactory Dysfunction: A Systematic Review

Review

作者: Vanderbroek, Annabelle ; Moyaert, Mathilde ; Clijsters, Marnick ; Van Gerven, Laura ; Bischoff, Sabrina

PURPOSE OF REVIEW:

COVID -19 associated olfactory dysfunction is widespread, yet effective treatment strategies remain unclear. This article aims to provide a comprehensive systematic review of therapeutic approaches and offers evidence-based recommendations for their clinical application.

RECENT FINDINGS:

A living Cochrane review, with rigorous inclusion criteria, has so far included 2 studies with a low certainty of evidence. In this systematic review we list clinical data of 36 randomised controlled trials (RCTs) and non-randomised studies published between Jan 1, 2020 and Nov 19, 2023 regarding treatment options for COVID-19 associated olfactory dysfunction. Nine treatment groups were analysed, including olfactory training, local and systemic corticosteroids, platelet-rich plasma (PRP), calcium chelators, vitamin supplements including palmitoylethanolamide with luteolin, insulin, gabapentin and cerebrolysin. Primary objective was the effect of the studied treatments on the delta olfactory function score (OFS) for objective/psychophysical testing. Treatments such as PRP and calcium chelators demonstrated significant improvements on OFS, whereas olfactory training and corticosteroids did not show notable efficacy for COVID-19 associated olfactory dysfunction.

2025-11-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Simultaneous analysis of four endocannabinoids and endocannabinoid congeners together with delta-9 tetrahydrocannabinol and related metabolites in dried blood spots

Article

作者: Richeval, Camille ; Gish, Alexandr ; Wiart, Jean-François ; Gaulier, Jean-Michel ; Allorge, Delphine

In the medical field, the endocannabinoid system is both a difficult and hot topic for scientific and media reasons (cannabis, cannabidiol, etc.). Due to their instability and low concentrations in blood and physicochemical properties, the complexity of endocannabinoid assay is previously reported in different matrices. This study aims to report a LC-MS/MS method for the simultaneous quantification of four endocannabinoids and endocannabinoid congeners: N-arachidonoylethanolamide (anandamide or AEA), 2-arachidonoylglycerol/1-arachidonoylglycerol (2-AG/1-AG), oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), together with Δ9-tetrahydrocannabinol (THC) and its main metabolites [11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) and 11-hydroxy- Δ9-tetrahydrocannabinol (11-OH THC] in Dried Blood Spot (DBS). This validated method reported LLOQs of 0.1 µg/L for AEA, 0.5 µg/L for THC and 11-OH THC, and 1 µg/L for OEA, PEA, 2AG and THC-COOH. The method demonstrated intra- and interassay accuracy and precision of less than 20 % for the LLOQ, and less than 15 % for the other calibration points. In particular, the stability carried out in this study demonstrated the practical applicability of DBS for the measurement of endocannabinoids in the whole blood. Therefore, we propose this method as a tool for basic and clinical research to support the growing interest of the scientific community in the endocannabinoid system.

2025-09-01·FOOD CHEMISTRY

A phenothiazine-based ratiometric fluorescent probe for detecting hypochlorite (ClO−) and its application in foods and water samples

Article

作者: Wang, Yuzhen ; Du, Mengqing ; Tian, Maozhong ; Yuan, Yuehua ; Shen, Siyi ; Zhu, Yongjun ; Yue, Chaoyi ; Wei, Jiyuan ; Feng, Feng ; Song, Jinping

As a significant reactive oxygen species (ROS), ClO^- plays versatile roles in daily life and many biological events. However, its abnormal levels are responsible for serious harm to human health. Therefore, it is of crucial interest to develop effective methods for detecting ClO^- in foods and living organisms. In this work, a novel fluorescent probe ethyl 2-(3-formyl-2-methoxy-10H-phenothiazin-10-yl)acetate (PEA) for detecting ClO^- was presented. It shows the merits of rapid ratiometric response (within 10 s), high selectivity and very large Stokes shift (190 nm). The detection limit of PEA for ClO^- was determined to be 0.47 μM. We not only successfully prepared paper test strips for efficient qualitative naked eye ClO^- detection, but also demonstrated its potential for the valid detection of ClO^- in natural water samples, beverages and foods. Furthermore, the probe PEA was also applied to the fluorescence imaging of ClO^- in onion epidermal cells.

125

项与帕米醇相关的新闻（医药）

2025-05-28

·EINPresswire

Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome

TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, FSD Pharma Australia Pty Ltd., that it has received approval by the human ethics review committee (HREC) in Australia for its trial entitled “A Randomized, Double-Blind Placebo Controlled Parallel Group Decentralized Trial to Assess the Safety and Efficacy of FSD202 in Participants with Chronic Widespread Musculoskeletal Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome (Disorder).” The randomized, double-blind, placebo controlled parallel group decentralized trial will enroll 60 patients with idiopathic Mast Cell Activation Syndrome (“ MCAS ”). Per the protocol, patients will receive FSD202 or placebo twice daily for 56 consecutive days. The primary outcome to be measured will be the decrease from baseline to Day 28 in the average daily pain intensity. The trial will also evaluate many secondary outcomes. MCAS refers to a group of disorders characterized by multisystem symptoms resulting from the accumulation of altered mast cells and/or abnormal mast cell mediator release, causing repeated anaphylactic symptoms/episodes and trapping a patient in a cycle of neurogenic pain and inflammation. Chronic widespread musculoskeletal nociplastic pain, a type of chronic pain characterized by altered pain perception that is not directly due to tissue injury, is associated with MCAS. The cause of MCAS is unknown and there currently is no cure. FSD202, a drug product containing ultra-micronized palmitoylethanolamide (PEA), has the potential to address a wide range of inflammatory diseases in addition to MCAS. This is especially important as chronic inflammatory diseases are the most significant cause of death globally and the World Health Organization ranks chronic disease as the greatest threat to human health. 1 “We are excited to evaluate the efficacy and safety of FSD202 in a Phase 2 trial for the treatment of nociplastic pain associated with idiopathic MCAS. These patients often have a significantly reduced quality of life and are in desperate need of safe alternatives to the current standard of care,” said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma. Zeeshan Saeed, CEO of Quantum BioPharma added, “We are delighted to receive HREC approval to proceed with our planned efficacy Phase 2 clinical trial of FSD202. Our clinical team has worked tirelessly to develop the clinical trial protocol and we are now looking forward to the next stages of clinical development for FSD202.” 1 Chronic Inflammation - StatPearls - NCBI Bookshelf (nih.gov); https://www-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/books/NBK493173/ About Quantum BioPharma Ltd. Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ Lucid ”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“ Celly Nutrition ”), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Celly Nutrition at www.unbuzzd.com . The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. For more information on Quantum BioPharma, please visit www.quantumbiopharma.com . Forward-Looking Information Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such. Forward-looking information in this press release are based on certain assumptions and expected future events. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law. Contacts: Quantum BioPharma Ltd. Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board Email: Zsaeed@quantumbiopharma.com Telephone: (833) 571-1811 Investor Relations Investor Relations: IR@QuantumBioPharma.com General Inquiries: info@QuantumBioPharma.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床2期

2025-05-27

·EINPresswire

SciSparc Announces Publication of Japanese Patent Application

TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the publication of a Japanese divisional patent. The patent application introduces a novel pharmaceutical combination of paracetamol and palmitoylethanolamide (PEA) that may enhance pain relief and fever relief with lower doses and fewer side effects compared to paracetamol monotherapy, with potential for safer and more effective treatment for millions worldwide. “This patent represents a significant innovation in pain management, that potentially could offer a safer alternative for patients of all ages for using this very common drug,” said Oz Adler, Chief Executive Officer of SciSparc. “This drug candidate combines paracetamol, a widely used pain reliever and fever reducer, with PEA, a natural compound that boosts the body’s endocannabinoid system. By working synergistically, the combination may reduce the required paracetamol dose, minimizing risks like liver damage while improving outcomes for acute, chronic, and neuropathic pain, as well as fever.” About SciSparc Ltd. (Nasdaq: SPRC): SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward looking statements when discussing the potential benefits and advantages of the novel pharmaceutical combination of paracetamol and PEA and that the patent represents a significant innovation in pain management, that potentially could offer a safer alternative for patients of all ages for using this very common drug. Since such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact: IR@scisparc.com Tel: +972-3-6167055 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025-04-25

·GlobeNewswire-Health Care

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders. The patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc’s Palmitoylethanolamide (“PEA”). This innovative combination aims to address the complex neurobiological and psychological factors associated with eating disorders, offering a potential new avenue for treatment. Eating disorders are serious mental health conditions that negatively impact an individual’s health, emotions, and ability to perform daily functions. Eating disorders are among the top ten leading causes of disability among young women and have one of the highest mortality rates compared to other mental disorders. According to recent studies, up to 70 million people globally are affected by eating disorders, with significant increases observed among children and adolescents. Global eating disorder prevalence increased from 3.4% to 7.8% between 2000 and 2018. About SciSparc Ltd. (Nasdaq: SPRC): SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on Amazon Marketplace. About Clearmind Medicine Inc. (“Clearmind”) Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Clearmind’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. Clearmind intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Common shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.” For further information visit: https://www.clearmindmedicine.com Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses the potential of its proprietary treatment to treat anorexia, bulimia and other eating disorders. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact:IR@scisparc.comTel: +972-3-6167055

100 项与帕米醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08328	帕米醇	J	DB14043

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
呼吸道感染	-	-	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肌肉骨骼疼痛	临床2期	美国	-	2023-01-19
慢性肌肉骨骼疼痛	临床2期	加拿大	-	2023-01-19
慢性疼痛	临床2期	美国	-	2023-01-19
慢性疼痛	临床2期	加拿大	-	2023-01-19
中链酰基辅酶A脱氢酶缺乏症	临床2期	美国	-	2023-01-19
中链酰基辅酶A脱氢酶缺乏症	临床2期	加拿大	-	2023-01-19
特发性肥大细胞活化综合征	临床2期	美国	-	2023-01-19
特发性肥大细胞活化综合征	临床2期	加拿大	-	2023-01-19
新型冠状病毒感染	临床2期	美国	Unbuzzd Wellness, Inc.	2020-12-14
Tourette 综合征	临床2期	美国	SciSparc Ltd.	2017-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05246670 (CTgov)	临床2期	化疗引起的损伤 \| 恶性实体肿瘤 \| 血液肿瘤 ... 更多	88	Quality-of-Life Assessment+Palmidrol (Lower-dose PEA)	淵膚獵獵鹹憲艱顧膚憲(積蓋鹹鏇觸築繭製鬱襯) = 網窪鹹鹹鹽齋顧觸鑰積範鹹觸觸鏇鹽鬱糧鏇顧 (繭膚醖糧選鹹膚遞獵繭, 5.42) 更多	-	2025-01-24
				Quality-of-Life Assessment+Palmidrol (Higher-dose PEA)	淵膚獵獵鹹憲艱顧膚憲(積蓋鹹鏇觸築繭製鬱襯) = 窪齋觸獵衊鏇網鏇願積範鹹觸觸鏇鹽鬱糧鏇顧 (繭膚醖糧選鹹膚遞獵繭, 12.24) 更多
ESMO2022	N/A	炎症	-	Palmitoylethanolamide	糧製鹹廠艱積觸艱壓憲(壓繭觸淵淵膚積積膚壓) = 齋壓範鏇鹽獵夢製襯餘鹹夢憲鑰齋夢積遞醖齋 (鑰憲顧蓋範顧淵觸蓋襯 )	-	2022-09-10
				Doxorubicin and trastuzumab	糧製鹹廠艱積觸艱壓憲(壓繭觸淵淵膚積積膚壓) = 築範齋觸鹽鬱獵夢顧艱鹹夢憲鑰齋夢積遞醖齋 (鑰憲顧蓋範顧淵觸蓋襯 )
ESC2021	N/A	-	-	Palmitoylethanolamide combined with polydatin	餘製築淵願糧膚製網餘(鹹齋鹽壓蓋淵構膚鹽觸) = 獵鏇餘積鹹顧鹽製觸鑰積積齋獵繭鹽顧夢淵廠 (範窪網繭鹽膚積襯襯壓 )	-	2021-06-29
				palmitoylethanolamide	餘製築淵願糧膚製網餘(鹹齋鹽壓蓋淵構膚鹽觸) = 選築範襯鬱淵醖鹽構齋積積齋獵繭鹽顧夢淵廠 (範窪網繭鹽膚積襯襯壓 )
Pubmed \| J Psychiatr Res	N/A	自闭症	-	Risperidone + Palmitoylethanolamide	衊簾築製製製製網蓋鏇(獵鑰糧築糧願鹽廠膚積): Cohen's d = 0.94 (95% CI, 0.41 ~ 1.46), P-Value = 0.001	-	2018-08-01
				Risperidone + Placebo
ISRCTN72647928 (Pubmed \| Invest Ophthalmol Vis Sci)	N/A	高血压	40	Palmitoylethanolamide 300 mg	餘繭網觸構鏇製構壓選(鹽壓鬱願鏇選憲鹹淵廠) = 構繭鏇構鬱遞窪壓製選夢糧網繭蓋襯壓憲遞襯 (艱獵淵膚憲艱廠蓋憲廠 ) 更多	积极	2013-02-01
				Placebo	餘繭網觸構鏇製構壓選(鹽壓鬱願鏇選憲鹹淵廠) = 鑰鑰鹹選願夢憲積艱衊夢糧網繭蓋襯壓憲遞襯 (艱獵淵膚憲艱廠蓋憲廠 ) 更多
ISRCTN72647928 (ARVO2012)	N/A	高血压	40	Palmitoylethanolamide	壓鏇簾顧製艱膚憲廠鬱(積鏇範糧製鏇觸鏇簾淵) = no side effects during the treatment period were observed 鑰構鏇醖觸選鹹簾憲鏇 (鏇願鹽繭獵憲膚獵選窪 )	-	2012-03-01
				Placebo